Market Overview

PetMed Posts In Line Q1 Earnings, Revenues on Lower Orders

Share:
America's largest pet pharmacy, PetMed Express (NASDAQ: PETS) reported earnings per share (ETF:EPS) of 25 cents in the first quarter of fiscal 2015, on par with the Zacks Consensus Estimate. However, the number remained a penny ahead of the comparable year-ago number. 

 

On the other hand, net sales in the quarter dropped 2.2% year over year to $72.5 million but remained almost in line with the Zacks Consensus Estimate. Year-over-year sales were negatively impacted by decreases in new order and reorder sales. According to the company, the demand was soft for flea and tick topical in the reported quarter. Despite that, the average order size has increased to $78 in the quarter from $77 a year ago.
 
During the quarter under review, PetMed acquired 184,000 new customers, down from 207,000 in the first quarter of fiscal 2014. Roughly 80% of all orders were generated from its website (versus 79% in the prior-year quarter). 
 
Gross margin expanded 41 basis points (bps) year over year to 32.8% due to cost reduction in certain brands. General and administrative expenses remained unchanged year over year at $5.8 million with a 4.8% drop in advertising expenses to $9.9 million. This led to a 3.1% reduction in operating expenses (without depreciation), which amounted to $15.1 million. Accordingly, adjusted operating margin expanded 59 bps to 11.0%.
 
PetMed exited the quarter with cash and cash equivalents and short-term investments of $44.7 million compared with $33.8 million at the end of fiscal 2014.
 
Recommendation
 
PetMed reported an ordinary performance in the fourth quarter with in-line earnings and revenues. Declining new order sales due to an increase in customer acquisition cost and lesser advertising remains a matter of concern. Although operating margins improved this quarter, the company expects no improvement in margin trend in the coming year.
 
However, we are encouraged by PetMed's cost reduction initiatives. Moreover, the company is currently trying to implement several strategies to revive its top line. These strategies include focusing on advertising efficiency to improve new order sales and shifting sales to higher margin items like generics, while also expanding its product offerings.
 
PetMed currently offers a wide range of products catering to dogs, cats and horses, and is working on upgrading its existing portfolio. The stock carries a Zacks Rank #2 (Buy).
 
Other Stocks to Consider
 
Some other well-ranked stocks in the broader medical sector are Mead Johnson Nutrition Company (NYSE: MJN), CareFusion Corporation (NYSE: CFN) and Alere Inc. (NYSE: ALR), all with the same Zacks Rank as PetMed.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PETMED EXPRESS (NASDAQ: PETS): Free Stock Analysis Report
 
CAREFUSION CORP (NYSE: CFN): Free Stock Analysis Report
 
ALERE INC (NYSE: ALR): Free Stock Analysis Report
 
MEAD JOHNSON NU (NYSE: MJN): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: Earnings News

 

Related Articles (CFN + ALR)

View Comments and Join the Discussion!